14 March 2023Optimizing photobiomodulation in the in vitro and in vivo models towards effective therapy of Alzheimer's disease (Conference Presentation)
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
A significant amount of recent studies reported use of photobiomodulation (PBM) to slow down the progression of Alzheimer’s disease. Less reports on improving the PBM therapeutic efficiency by optimizing light parameters. Our findings demonstrate that PBM effect in in vitro and in vivo AD models significantly depends on wavelength, dose and mode (continuous wave or pulsed) of irradiation. While the viability and anti-inflammatory activity of amyloid-β (Aβ) treated cultured neurons and microglia were improved after irradiation with 808 nm light, Aβ plagues accumulation and cerebral amyloid angiopathy in the AD mice brain were best attenuated after stimulation with 40 Hz pulsed 808 nm or spectrally broad visible light, which also improved spatial learning and memory abilities.Future research can involve simultaneous or sequential stimulation with visible and NIR pulsed light in optimize wavelengths, dose and frequencies to achieve efficient AD therapy.
Hao Xu,Tymish Y. Ohulchanskyy, andJunle Qu
"Optimizing photobiomodulation in the in vitro and in vivo models towards effective therapy of Alzheimer's disease (Conference Presentation)", Proc. SPIE 12380, Biophotonics and Immune Responses XVIII, 1238009 (14 March 2023); https://doi.org/10.1117/12.2651226
ACCESS THE FULL ARTICLE
INSTITUTIONAL Select your institution to access the SPIE Digital Library.
PERSONAL Sign in with your SPIE account to access your personal subscriptions or to use specific features such as save to my library, sign up for alerts, save searches, etc.
The alert did not successfully save. Please try again later.
Hao Xu, Tymish Y. Ohulchanskyy, Junle Qu, "Optimizing photobiomodulation in the in vitro and in vivo models towards effective therapy of Alzheimer's disease (Conference Presentation)," Proc. SPIE 12380, Biophotonics and Immune Responses XVIII, 1238009 (14 March 2023); https://doi.org/10.1117/12.2651226